BioSpace News Archive

Deals

Bristol Myers Squibb to Hold Virtual Three-Part Investor Series

Bristol Myers Squibb announced that it will hold a virtual three part investor series during the week of June 22, 2020.

May 29, 2020
·
1 min read
Policy

AVEO Oncology Announces TIVO-3 Final Overall Survival Results Featured at ASCO 2020 Virtual Scientific Program and Submitted to U.S. FDA as Part of NDA Filing

AVEO Oncology announced the presentation of results from the final analysis of overall survival in its pivotal Phase 3 TIVO-3 trial comparing tivozanib, the Company’s next-generation vascular endothelial growth factor receptor tyrosine kinase inhibitor, to sorafenib in 3rd and 4th line renal cell carcinoma.

May 29, 2020
·
10 min read
Biotech Bay

BridgeBio Pharma’s QED Therapeutics Presents Data on Infigratinib in Cholangiocarcinoma and Urothelial Carcinoma at the American Society of Clinical Oncology 2020 Virtual Scientific Program

BridgeBio Pharma, Inc. affiliate QED Therapeutics announced that it will present data at the American Society of Clinical Oncology 2020 Virtual Scientific Program showing clinical advancement for infigratinib, QED’s oral FGFR1-3 inhibitor, in both urothelial carcinoma and cholangiocarcinoma.

May 29, 2020
·
6 min read
Policy

Johnson & Johnson Receives Positive CHMP Opinion for Janssen’s Investigational Preventive Ebola Vaccine Regimen

The investigational Ebola vaccine regimen leverages Janssen’s established AdVac® and PER.C6® technologies and Bavarian Nordic’s MVA-BN® technology

May 29, 2020
·
14 min read
Autolus Therapeutics presents additional data on AUTO3 in DLBCL during the ASCO20 Virtual Scientific Program

Data continue to show encouraging clinical activity alongside tolerable safety to deliver a potentially highly differentiated product profile

May 29, 2020
·
6 min read
Drug Development

Agios Presents Updated Data from the Phase 1 Dose-escalation Study of Vorasidenib in Patients with IDH-mutant Non-enhancing Glioma

Vorasidenib Demonstrated Prolonged Disease Control and Encouraging Preliminary Activity with Median Progression-free Survival of 31.4 Months

May 29, 2020
·
9 min read
Genetown

Genocea Presents Updated Long-term Safety, Immunogenicity and Durability Data from GEN-009 Neoantigen Vaccine Phase 1/2a Trial Part A at Virtual ASCO 2020

Data show immune responses occur rapidly after only two vaccinations and can be sustained for more than one year

May 29, 2020
·
4 min read
Drug Development

Trillium Therapeutics Provides Update on the Phase I Dose Escalation Study of Its CD47 Blocker TTI-622 at the ASCO20 Virtual Scientific Program

Trillium Therapeutics Inc., a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced data from an ongoing phase 1 dose escalation study of TTI-622 in patients with advanced relapsed or refractory lymphoma.

May 29, 2020
·
5 min read
Biotech Bay

Corvus Pharmaceuticals Presents Updated Clinical Data Supporting and Refining the Adenosine Gene Signature’s Ability to Identify Patients Likely to Respond to Treatment with Ciforadenant

Elucidation of CD68 as a Downstream Target of Adenosine Refines Adenosine Gene Signature into a Practical Pathology Test Provides Opportunity to Further Enrich Patient Selection for Responders

May 29, 2020
·
8 min read
Drug Development

eFFECTOR’s Tomivosertib Demonstrates Positive Phase 2 Results for Subjects with Non-Small Cell Lung Cancer in Combination with Checkpoint Inhibitors

eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulation inhibitors for the treatment of cancer, announced that positive Phase 2 data from its pipeline program tomivosertib, will be presented at the ASCO 2020 Virtual Scientific Program at 8:00 a.m. ET on May 29.

May 29, 2020
·
3 min read